List of Clinical Trials

Updated October 9, 2018

In addition to the therapies approved by Health Canada, patients may be able to access several other therapies through clinical trials. By participating in a clinical trial, you will be helping researchers answer important questions that will further the development of new treatments and new treatment guidelines. Also, clinical trials often give you another option in your treatment plan.

Kidney Cancer Canada makes every effort to be aware of major clinical trials for renal cell carcinoma across Canada. As a patient with renal cell carcinoma, you may be eligible to access a therapy through a clinical trial depending upon:

  • Your sub-type of kidney cancer (e.g., clear cell renal cell carcinoma or other)
  • Your stage of disease (e.g., whether or not you have metastasis)
  • Whether you have had one or more prior therapies

For ease of reference, we have organized major clinical trials into groupings below according to where you are on the treatment journey. For example, you’ll find trials for patients who have just recently been diagnosed and are pre-surgery or clinical trials for those for patients who have already had several systemic therapies.

 

Diagnostic / Imaging Trials

Diagnostic trials look at what tests (such as blood, laboratory or imaging tests), or procedures are best at finding (detecting) kidney cancer or seeing if kidney cancer has come back (recurred).

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01353521

Contrast-enhanced Ultrasound to Evaluate Complex Renal Cysts.

Purpose:

  • This study is looking at whether an imaging technique, called contrast-enhanced ultrasound (CEUS), can be used to accurately view complex kidney (renal) cysts. Complex kidney cysts can have many, thickened or irregular walls and may contain areas of calcification, which is a build up of calcium. Some complex cysts are more likely to be associated with cancerous changes. Complex kidney cysts are usually assessed using CT scans or MRIs. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
St. Joseph’s Healthcare Hamilton Dr Anil Kapoor Hamilton, ON Recruiting

 

2 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01141816

Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation (RFA) of Kidney Lesions.

Purpose:

  • This study will be looking at whether a different technique, called contrast-enhanced ultrasound (CEUS), can be used to effectively follow patients who have had radiofrequency ablation (RFA) treatment for a kidney lesion or kidney tumour. At this time, follow-up after treatment involves the patient having CT scans (or MRIs) over time to see if their kidney cancer has come back (recurred). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
St. Joseph’s Healthcare Hamilton  Dr Anil Kapoor Hamilton, ON Recruiting

 

3 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02428335

A Study of Muscle Energy Metabolism in Patients With Renal Cell Cancer (RCC) Treated With Sunitinib.

Purpose:

  • This study will use a special type of scan (called technetium-99m sestamibi) to study fatigue in kidney cancer patients taking sunitinib (Sutent®). Fatigue is a very common side effect of the targeted therapy sunitinib, but what causes it is not known. The study will look at the effect sunitinib has on muscle cells using the technetium-99m sestamibi scan. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute  Dr Michael Sawyer Edmonton, AB Pending

 

4 KIDNEY CANCER TYPE: 
TRIAL ID: NCT00323076

Imaging Study in Patients With Cancer of the Head and Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours.

Purpose:

  • This study is looking at the safety and effectiveness of PET scanning using a special PET tracer called 18F-FAZA, in patients with different types of cancer including kidney cancer. A Positron Emission Tomography scan (or PET scan) uses a special dye to help find cancer cells in the body. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute  Dr Alexander McEwan Edmonton, AB Recruiting

 

5 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01065805

A Study to Demonstrate the Safety and Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma.

Purpose:

  • This is a study to see how safe and effective imaging with the radiotracer 18F-FLT and PET scanning is in patients with a number of known or suspected solid tumours, including kidney cancer. 18F-FLT can help detect increased cell growth in PET scan images. Imaging and measuring cell growth with 18F-FLT may be helpful to monitor how a kidney cancer patient has responded to treatment. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute  Dr Alexander McEwan Edmonton, AB Recruiting

Prognostic / Predictive Trials

Studies may be done to look at certain factors or characteristics of a patient or their cancer cells that provide information on the likely outcome (prognosis) of a patient with kidney cancer. Studies may also be done to see what might predict how a kidney cancer patient will respond to treatment (predictive factor).

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT02499458

Prospective Validation of Circulating Tumour Cells and Circulating Endothelial Cells as Biomarkers in Clear Cell Kidney Cancer.

Purpose:

  • Circulating tumour cells (CTCs) have prognostic value in many tumour types and may help researchers better understand and address how patients respond to treatment or why their tumour becomes resistant to certain treatments. This study will look at a new CTC technology to study metastatic clear cell kidney cancer with the hope that it can give better information and help improve the treatment of patients with this type of kidney cancer. Find out more about this study
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
London Health Sciences Centre Dr Alison Allan London, ON Recruiting

Active Surveillance Trials

Active surveillance uses a watch-and-wait approach, keeping a close watch on a patient’s kidney cancer, but waiting to start treatment until it starts to grow or cause problems.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01305330

The Natural History of Small Renal Masses.

Purpose:

  • Small kidney (renal) masses are less than 4 cm. Most small kidney masses grow slowly and might not need treatment right away, while some grow quickly and should be treated. This study will watch newly diagnosed patients with small kidney tumours. Researchers will use imaging studies and tissue tests to try to find out which kidney masses are more likely to grow and behave more aggressively and should be treated. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network Dr Michael Jewett Toronto, ON Recruiting

Ablative Treatment Trials

Ablative therapies, or tumour ablation techniques, are treatments that destroy kidney cancer cells in a certain way. For example, thermal ablative procedures use extreme temperatures such as heat or cold to destroy cancer cells.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01720706

A Study of Thermal Ablation for Treating Larger Liver and Kidney Tumours.

Purpose:

  • This study is looking at how safe and effective a newer way of giving radiofrequency ablation (RFA) treatment is compared to the standard RFA to treat larger tumours in the kidney or liver. Using a new device, a current passes from a coil (electrode) into the tissue and heats the tissue in the area of the electrode. This procedure will be done before a patient has surgery with a partial or radical nephrectomy. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network Dr Michael Jewett Toronto, ON Recruiting

Before Surgery (Neoadjuvant) Treatment Trials

Neoadjuvant trials test whether certain treatments given before the main treatment, which is usually surgery, help reduce the size of kidney tumours. Types of neoadjuvant treatments include drug therapy, radiation therapy or other treatments.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: Any type including clear cell, sarcomatoid or unclassified
TRIAL ID: NCT03055013

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Surgery with a Nephrectomy (also called PROSPER RCC Study).

Purpose:

  • This study is comparing surgery to remove part or all of a kidney (partial or total nephrectomy) to surgery plus the drug nivolumab (Opdivo®), to treat patients with kidney cancer that has not spread to other parts of the body (is localized). Nivolumab in an immuno-oncology drug and may interfere with the ability of tumour cells to grow and spread. Giving nivolumab before a nephrectomy may make the tumour smaller and reduce the amount of normal tissue that needs to be removed. In this study, nivolumab will also be given after the nephrectomy to see if it increases a patient’s chances for survival. It is not yet known whether the combination of nivolumab and nephrectomy works better than nephrectomy only in treating patients with kidney cancer. This trial is for patients who are newly diagnosed with kidney cancer and have a high risk of their cancer coming back. Patients can have clear cell, sarcomatoid or unknown (unclassified) types of kidney cancer. One group of patients will be given nivolumab before and after their surgery. The other group of patients will have surgery followed by close observation (active surveillance). This study is not for patients with advanced kidney cancer, whose cancer has spread beyond the kidney (metastasized). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Tom Baker Cancer Centre Dr Daniel Heng Calgary, AB Pending
Juravinski Cancer Centre Dr Anil Kapoor Hamilton, ON Pending

Surgery Trials

Surgery to remove the tumour is the mainstay of kidney cancer treatment. Surgery trials test new ways of doing kidney cancer surgery or new devices or technologies to use during surgery to help protect kidney function.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

THERE ARE NO CLINICAL TRIALS FOR THIS CATEGORY AT THIS TIME.

After Surgery (Adjuvant) Treatment Trials

The purpose of adjuvant trials is to find out whether additional treatment given after kidney cancer surgery – which is the main treatment for kidney cancer - helps slow or reduce the risk of cancer coming back. Types of adjuvant treatments include drug therapy, radiation therapy or sometimes other treatments.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: Clear cell or sarcomatoid
TRIAL ID: NCT03024996

A Study of Atezolizumab as Adjuvant Therapy in Patients with Kidney Cancer at High Risk of Developing Metastasis After a Nephrectomy (also called IMmotion010).

Purpose:

  • This study is looking at how safe and effective a drug called atezolizumab (MPDL3280A, Tecentriq®) is when given after surgery for kidney cancer (nephrectomy). There will be two groups in this study; one group of the patients in the trial will get atezolizumab while the other group will get a placebo. Atezolizumab is a newer immuno-oncology therapy and a PD-L1 checkpoint inhibitor. A placebo is an inactive drug or treatment that looks like and is given the same way as the active drug or treatment in the trial. Patients and their healthcare team will not know who is getting the atezolimuab or who is getting the placebo. This trial is for patients with kidney cancer who are considered to have a high risk of their cancer coming back (recurring) or spreading (metastasizing) after nephrectomy surgery. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency - Centre for the Southern Interior Dr Daygen Finch Kelowna, BC Recruiting
Cross Cancer Agency Dr Scott North Edmonton, AB Recruiting
Tom Baker Cancer Centre Dr Daniel Heng Calgary, AB Recruiting
North York General Hospital   Toronto, ON Recruiting
Ottawa Hospital Cancer Centre   Ottawa, ON  Recruiting
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Princess Margaret Cancer Centre | University Health Network Dr Aaron Hansen Toronto, ON Recruiting
Centre universitaire de santé McGill | McGill University Health Centre - Glen Site Dr Simon Tanguay Montréal, QC Recruiting
Centre hospitalier universitaire
de Sherbrooke - CHUS
Dr Michel Pavic Sherbrooke, QC Recruiting 
Hôtel-Dieu de Québec | CHU de Québec Dr Louis Lacombe Québec, QC Recruiting
QEII Health Sciences Centre Dr Lori Wood Halifax, NS Recruiting

 

2 KIDNEY CANCER TYPE: Clear cell component with or without sarcomatoid features
TRIAL ID: NCT03142334

A Study of Pembrolizumab as Adjuvant Therapy in Patients After a Nephrectomy (also called Keynote-564).

Purpose:

  • This study is looking at how safe and effective the drug pembrolizumab (Keytruda®, MK-3475) is when given after surgery for kidney cancer (nephrectomy).  There will be two groups in this study; one group of patients in the trial will get pembrolizumab, while the other group will get a placebo. Pembrolizumab is a newer immuno-oncology therapy and a PD-L1 checkpoint inhibitor. A placebo is an inactive drug or treatment that looks like and is given the same way as the active drug or treatment in the trial. Patients and their healthcare team will not know who is getting the pembrolizumab or who is getting the placebo. This trial is for patients with kidney cancer who are considered to have an intermediate to high risk of their cancer coming back (recurring) or spreading after nephrectomy surgery. It is also for patients having a nephrectomy and one site of metastasis that can be completely removed by surgery. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Saskatoon Cancer Centre   Saskatoon, SK Recruiting
Allan Blair Cancer Centre   Regina, SK Recruiting
William Osler Health System   Brampton, ON Closed
London Regional Cancer Program | London Health Sciences Centre Dr Eric Winquist London, ON Recruiting
R.S. McLaughlin Durham Regional Cancer Centre   Oshawa, ON Recruiting
Hôtel-Dieu de Lévis | CISSS de Chaudière-Appalaches   Lévis, QC Recruiting
CIUSSS du Saguenay-Lac-St-Jean   Chicoutimi, QC Recruiting
Recherche médicale Saint-Jérôme Inc.   Saint-Jérôme, QC Recruiting
Dr. Léon-Richard Oncology Centre   Moncton, NB Recruiting

 

3 KIDNEY CANCER TYPE: Mainly clear cell and can have sarcomatoid features
TRIAL ID: NCT03138512

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Patients With Localized Kidney Cancer (also called CheckMate 914).

Purpose:

  • This study is looking at whether the drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) when given together, are safe and effective for delaying or preventing a recurrence of cancer in patients who have had part or all of their kidney removed (partial or radical nephrectomy) because of kidney cancer. There will be two groups in this study; one group of patients in the trial will get nivolumab and ipilimumab, while the other group of patients will get a placebo. Nivolumab and ipilimumab are both immuno-oncology drugs, but they work in slightly different ways. A placebo is an inactive treatment (drug) that looks like and is given the same way as the active drug or treatment in the trial. Patients and their healthcare team will not know who is getting the drug combination or who is getting the placebo. This study is for patients who are at a high risk of their kidney cancer coming back (recurring) after nephrectomy surgery. It is not for patients whose kidney cancer has already spread (metastasized). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency   Vancouver, BC Recruiting
R.S. McLaughlin Durham Regional Cancer Centre   Oshawa, ON Recruiting
Princess Margaret Cancer Centre   Toronto, ON Recruiting
Hôpital Notre-Dame du CHUM   Montréal, QC Pending
Hôpital régional de Rimouski   Rimouski, QC Recruiting
Saint John Regional Hospital   Saint John, NB Recruiting

 

4 KIDNEY CANCER TYPE: Any type including clear cell, sarcomatoid or unclassified
TRIAL ID: NCT03055013

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Surgery with a Nephrectomy (also called PROSPER RCC Study).

Purpose:

  • This study is comparing surgery to remove part or all of a kidney (partial or total nephrectomy) to surgery plus the drug nivolumab (Opdivo®), to treat patients with kidney cancer that has not spread to other parts of the body (is localized). Nivolumab in an immuno-oncology drug and may interfere with the ability of tumour cells to grow and spread. Giving nivolumab before a nephrectomy may make the tumour smaller and reduce the amount of normal tissue that needs to be removed. In this study, nivolumab will also be given after the nephrectomy to see if it increases a patient’s chances for survival. It is not yet known whether the combination of nivolumab and nephrectomy works better than nephrectomy only in treating patients with kidney cancer. This trial is for patients who are newly diagnosed with kidney cancer and have a high risk of their cancer coming back. Patients can have clear cell, sarcomatoid or unknown (unclassified) types of kidney cancer. One group of patients will be given nivolumab before and after their surgery. The other group of patients will have surgery followed by close observation (active surveillance). This study is not for patients with advanced kidney cancer, whose cancer has spread beyond the kidney (metastasized). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Tom Baker Cancer Centre Dr Daniel Heng Calgary, AB Pending
Juravinski Cancer Centre Dr Anil Kapoor Hamilton, ON Pending

Radiation Treatment Trials

Radiation therapy trials test different ways of giving radiation or combining radiation with other cancer treatments to better treat patients with kidney cancer.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

1 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT02019576

Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib (also called OZM-053 Study).

Purpose:

  • Stereotactic Radiation Therapy (SRT) is a newer way of giving radiation in a very precise and accurate way to tumours. It delivers a high dose of radiation to a tumour, while sparing much of the nearby normal tissue and organs. This study will measure how well SRT can destroy tumours in patients taking the targeted therapy sunitinib (Sutent®) for their kidney cancer. Researchers want to see how much longer SRT can help patients stay on sunitinib before they need to be switched to another drug treatment. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency Dr Christian Kollmannsberger Vancouver, BC Recruiting
Tom Baker Cancer Centre Dr Gerald Lim Calgary, AB Recruiting
Cross Cancer Institute Dr Samir Patel Edmonton, AB Recruiting
CancerCare Manitoba Dr Arbind Dubey Winnipeg, MB Recruiting
Juravinski Cancer Centre | Hamilton Health Sciences Centre Dr Anand Swaminath Hamilton, ON Recruiting
London Health Sciences Centre Dr Belal Ahmad London, ON  Recruiting 
Ottawa Hospital Cancer Centre Dr Scott Morgan  Ottawa, ON  Recruiting 
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason &
Dr Patrick Cheung
Toronto, ON Recruiting 
Princess Margaret Cancer Centre | University Health Network Dr Srikala Sridhar Toronto, ON Recruiting
Hôpital général juif | Jewish General Hospital Dr Tamim Niazi Montréal, QC Recruiting
Centre universitaire de santé McGill | McGill University Health Centre Dr Fabio Cury Montréal, QC Recruiting
QEII Health Sciences Centre Dr Lori Wood Halifax, NS Recruiting 

 

2 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT02978404 

Combining Radiosurgery and Nivolumab (Opdivo®) to Treat Brain Metastases (also called OZM-080 study).

Purpose:

  • This study is looking at how well combining stereotactic radiosurgery (SRS), which is radiation given in a more focused and precise way, with an immuno-oncology drug called nivolumab (Opdivo®) works to treat kidney cancer patients when their cancer has spread to the brain (brain metastases). Researchers want to see if nivolumab and SRS can trigger an immune reaction in patients with clear cell kidney cancer and reduce new brain metastases from developing. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Centre hospitalier de l'Université de Montréal (CHUM)  Dr Philip Wong Montréal, QC Recruiting
Centre universitaire de santé McGill (CUSM) | McGill University Health Centre - Glen Site (MUHC) Dr Valérie Panet-Raymond Montréal, QC Pending
Centre hospitalier universitaire de Sherbrooke Dr Marc-Émile Plourde Sherbrooke, QC Recruiting

 

3 KIDNEY CANCER TYPE:
TRIAL ID: NCT01761929 

A Five Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases.

Purpose:

  • Stereotactic Body Radiation Therapy (SBRT) delivers higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues. This study is looking at what side effects and how well 5 treatments of SBRT work in patients with solid tumours (including kidney cancer) whose cancer has spread to a limited number of areas such as the lung, bone, liver or adrenal gland, but not within the skull (extra-cranial). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network  Dr Rebecca Wong Toronto, ON Recruiting

   

4 KIDNEY CANCER TYPE: Clear cell component
TRIAL ID: NCT02599779

A Proof of Principle Study of the Activity of Pembrolizumab Given in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer, or mRCC (also called OZM-065 Study)

Purpose:

  • Patients who have stopped responding to one prior targeted therapy with a tyrosine kinase inhibitor (TKI), are considered TKI refractory and can take part in this study. This study is for patients with stage IV (metastatic) kidney cancer. Pembrolizumab (MK-3475, Keytruda®) is a newer immuno-oncology drug. SBRT is a very precise way of giving radiation therapy to tumours. SBRT will be given with pembrolizumab to see how well this combination of treatments works in patients with metastatic kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency  Dr Christian Kollmannsberger Vancouver, BC Pending
Tom Baker Cancer Centre Dr Richard Lee-Ying Calgary, AB Recruiting
Princess Margaret Hospital | University Health Network Dr Aaron Hansen Toronto, ON Recruiting
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Ottawa Hospital Cancer Centre Dr Christina Canil Ottawa, ON Pending

 

5 KIDNEY CANCER TYPE: 
TRIAL ID: NCT03108703

Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (also called AQuOS-RCC Study).

Purpose:

  • Purpose: Stereotactic Body Radiotherapy (SBRT) is a newer radiation therapy technique that precisely delivers high doses of radiation to tumours. This study will be looking at the quality of life (QoL) and outcomes in patients receiving SBRT treatment for their kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr William Chu Toronto, ON Recruiting
Juravinski Cancer Centre | Hamilton Health Sciences Centre Dr Anand Swaminath Hamilton, ON Recruiting

Drug Treatment Trials

Drug trials test a new drug, different combinations of drugs, or using different dosages and schedules for giving drugs to better treat patients with kidney cancer. Drug trials also test how safe, effective and what side effects a new drug or combination of drugs may have. 

Because most kidney cancers do not respond well to chemotherapy, these studies often focus on using new or different combinations of drugs, such as targeted or immuno-oncology therapies. The studies listed below are mainly for patients whose cancer has spread from where it started in the kidney to nearby tissue or lymph nodes (locally advanced) or spread to other parts of the body (metastatic) kidney cancer.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned.

 

 

 

 

Trials for patients who have not had any previous drug treatment

 

1 KIDNEY CANCER TYPE: Papillary
TRIAL ID: NCT02761057

Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (also called PAPMET Study).

Purpose:

  • This study is looking at how effective cabozantinib (Cometriq®, BMS-907351), or crizotinib (Xalkori®), or volitinib (AZD6094, Savolitinib), or sunitinib (Sutent®) each is in treating patients with papillary kidney cancer that is locally advanced or has spread (metastasized). Cabozantinib, crizotinib and volitinib are drugs called MET inhibitors. Sunitinib is a targeted tyrosine kinase inhibitor (TKI) therapy. This study is looking to see which of these drugs can stop the growth of tumour cells by blocking some of the enzymes needed for cell growth. Patients may have had prior surgery, 1 prior drug ( systemic) therapy or prior radiation therapy for advanced or metastatic kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute Dr Naveen S. Basappa Edmonton, AB Recruiting
Tom Baker Cancer Centre Dr Daniel Heng Calgary, AB Recruiting
London Regional Cancer Program Dr Kylea Potvin London, ON Recruiting
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Saint Joseph's Healthcare | Charlton Campus Dr Anil Kapoor Hamilton, ON Recruiting
Ottawa Hospital and Cancer Centre Dr Christina Canil Ottawa, ON Suspended
Centre hospitalier de l'Université de Montréal - CHUM Dr Jean-Baptiste Lattouf Montréal, QC Recruiting
QEII Health Sciences Centre | Capital District Health Authority Dr Lori Wood  Halifax, NS Recruiting

 

2 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02996110

A Study to Test Combination (Immuno-oncology Drug) Treatments in Patients With Advanced Kidney Cancer (also called FRACTION-RCC).

Purpose:

  • This study is for patients with advanced or metastatic kidney cancer. It is being done to find out whether the drug nivolumab (Opdivo®) when given along with experimental immune-oncology drug therapies, is more effective than using the combination of nivolumab and ipilimumab (Yervoy®). Nivolumab, ipilimumab, relatlimab (BMS-986016) and BMS-986205 are all immuno-oncology drugs, which each work in slightly different ways.  One group of patients will be given the combination of nivolumab and ipilimumab. One group of patients will be given nivolumab and the experimental immuno-oncology drug called relatlimab (BMS-986016). Another group of patients will be given nivolumab and the experimental drug BMS-986205. This study does not specify if it is for kidney cancer patients who may or may not have had prior drug treatments, so please check with your doctor to see if this trial might be an option for you. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
R.S. McLaughlin Durham Regional Cancer Centre    Oshawa, ON Recruiting
Princess Margaret Centre | University Health Network   Toronto, ON Pending
Juravinski Cancer Centre | Hamilton Health Sciences Centre Dr Sebastian Hotte Hamilton, ON Recruiting
Hôpital général juif | Jewish General Hospital Dr Wilson H. Miller Jr Montréal, QC Recruiting
Hôptial Hôtel-Dieu de Québec - CHUQ Dr Vincent Fradet Québec, QC Recruiting

 

3 KIDNEY CANCER TYPE: Clear cell component
TRIAL ID: NCT02811861

A Study to Compare the Effectiveness and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone as a First-Line Treatment of Patients with Advanced Kidney Cancer (also called the CLEAR Study).

Purpose:

  • This study is for patients with advanced kidney cancer who have not had any prior drug treatment. It is being done to find out whether the drug combination of lenvatinib (Lenvima®) and everolimus (Afinitor®), or lenvatinib and pembrolizumab (MK-3475, Keytruda®) is more effective than using sunitinib (Sutent®) by itself. The safety of lenvatinib used with everolimus and pembrolizumab will also be studied. Sunitinib is a targeted therapy drug currently used to treat kidney cancer. Lenvatinib is a targeted therapy that works much like sunitinib. Everolimus is a targeted therapy mTOR inhibitor drug. Pembrolizumab is a newer immuno-oncology drug. One group of patients will be given the combination of lenvatinib and everolimus. Another group of patients will get lenvatinib and pembrolizumab. The last group of patients will be treated with sunitinib alone. Find out more about this study
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency   Vancouver, BC Pending
London Regional Cancer Centre Dr Eric Winquist London, ON Recruiting
Juravinski Cancer Centre | Hamilton Health Sciences Centre   Hamilton, ON Recruiting
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Ottawa Hospital and Cancer Centre   Ottawa, ON Recruiting
Hôpital Charles-Le Moyne | CISSS de la Montrérégie-Centre   Greenfield Park, QC Recruiting

 

4 KIDNEY CANCER TYPE: Clear cell component and/or sarcomatoid component
TRIAL ID: NCT03063762

A Study to Check the Safety, Drug Action and Effectiveness of RO6874281 as a Combination Therapy in Patients With Unresectable Advanced or Metastatic Kidney Cancer.

Purpose:

  • This study is for patients with advanced or metastatic kidney cancer who have not had any prior drug treatment for their kidney cancer and are not able to have surgery (their cancer is unresectable). It is being done to find out how safe, effective and how patients tolerate the drug combination of RO6874281 and atezolizumab (MPDL3280A, Tecentriq®).  Another part of this study will also be looking at the safety, effectiveness and how patients tolerate these 2 drugs when given along with another drug called bevacizumab (Avastin®). RO6874281 is an experimental drug with immune-oncology action.  Atezolizumab is a newer immuno-oncology drug and a PD-L1 checkpoint inhibitor. Bevacizumab is a targeted therapy that may prevent tumours from growing new blood vessels that they need to grow. One group of patients will be given the combination of RO6874281 and atezolizumab. Another group of patients will get RO6874281, atezolizumab and bevacizumab. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network Dr Aaron Hansen Toronto, ON Recruiting

 

5 KIDNEY CANCER TYPE: Clear cell and can have sarcomatoid features
TRIAL ID: NCT03260894

Pembrolizumab (MK-3475) Plus Epacadostat versus Standard of Care Drug Therapy for Metastatic Kidney Cancer (also called KEYNOTE-679).

Purpose:

  • This study is for patients with locally advanced or metastatic kidney cancer who have not had any drug treatment before. It is being done to find out how safe and effective the drug combination of pembrolizumab (MK-3475, Keytruda®) and epacadostat (INCB024360) is compared to the standard of care, which is treatment with sunitinib (Sutent®) or pazopanib (Votrient®). Pembrolizumab is a newer immune-oncology drug. Sunitinib and pazopanib are both targeted therapy drugs. One group of patients will be given pembrolizumab and epacadostat. One group of patients will be given either sutent or pazaopanib. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Tom Baker Cancer Centre   Calgary, AB Pending
Sunnybrook Health Sciences | Odette Cancer Centre   Toronto, ON Closed
Kingston Health Sciences Centre | KGH Site   Kingston, ON Closed
Hôpital général juif | Jewish General Hospital   Montréal, QC Pending
Hôpital Notre-Dame du CHUM   Montréal, QC Closed
L'Hôtel-Dieu de Québec | CHU de Québec - Université Laval   Québec, QC Closed

 

6 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02983045

Dose Escalation and Expansion Study of NKTR-214 in Combination with Nivolumab or in Combination with Nivolumab and Ipilimumab in Patients With Certain Advanced or Metastatic Cancers, including Kidney Cancer (also called PIVOT-02).

Purpose:

  • This study is being done to find out the dose of NKTR-214 to give when used with nivolumab (Opdivo®). It is also studying how safe, effective and how a patient with advanced or metastatic kidney cancer tolerates the drug combination of NKTR-214 and nivolumab compared to the drug combination of NKTR-214, nivolumab and ipilimumab (Yervoy®). All these drugs target the immune system and may work better together to kill cancer cells. NKTR-214 is an experimental drug that targets CD122 specific receptors found on the surface of immune cells.  Nivolumab is an immune-oncology drug, an anti PD-1 drug that is used as a second-line treatment for kidney cancer in Canada.  Ipilimumab is also an immune-oncology drug, but it works on a different checkpoint protein (it is a CTLA-4 inhibitor drug). There are several parts to this study, some parts are for patients who have not had prior drug therapy for their kidney cancer, other patients can have had prior drug therapy. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency   Vancouver, BC Pending
Odette Cancer Centre | Sunnybrook Health Sciences Centre   Toronto, ON Recruiting
Princess Margaret Cancer Centre | University Health Network Dr Philippe Bedard Toronto, ON Recruiting
Hôpital général juif | Jewish General Hospital   Montréal, QC Pending

 

7 KIDNEY CANCER TYPE: Clear cell or non-clear cell
TRIAL ID: NCT02853344

A Study using Pembrolizumab (MK-3475) by Itself for Patients with Locally Advanced or Metastatic Kidney Cancer (also called MK-3475-427 or KEYNOTE-427 Study).

Purpose:

  • This study is for patients with locally advanced or metastatic (stage IV) or recurrent, clear cell or non-clear cell types of kidney cancer, who have never had any previous drug treatment for their kidney cancer. Pembrolizumab (MK-3475, Keytruda®) is a newer immuno-oncology drug. This study will be looking at how safe and effective pembrolizumab is in kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS

Cross Cancer Institute

  Edmonton, AB Closed
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Closed
Princess Margaret Cancer Centre | University Health Network Dr Srikala Sridhar Toronto, ON Closed
Merck Canada – We do not have a list of all participating centres. Talk to your doctor if you would like more information about this trial.   Kirkland, QC Closed

 

8 KIDNEY CANCER TYPE: Clear cell component with or without sarcomatoid features
TRIAL ID: NCT02853331 

A Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib by itself in Patients With Kidney Cancer (also called MK-3475-426/KEYNOTE-426 Study).

Purpose:

  • This study is for patients with locally advanced or metastatic (stage IV) kidney cancer, who have never had any previous drug treatment for their kidney cancer. Pembrolizumab (MK-3475, Keytruda®) is a newer immuno-oncology drug. Axitinib (Inlyta®) and sunitinib (Sutent®) are both targeted therapy drugs. This study will look at how safe and effective pembrolizumab and axitinib are when used together compared to sunitinib treatment by itself as an initial treatment in patients with kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Juravinski Cancer Centre | Hamilton Health Sciences  Dr Sebastien Hotte Hamilton, ON Closed
Merck Canada – We do not have a list of all participating centres. Talk to your doctor if you would like more information about this trial.   Kirkland, QC Closed

 

 

TRIALS FOR PATIENTS WHO HAVE HAD PREVIOUS DRUG TREATMENT

 

1 KIDNEY CANCER TYPE:
TRIAL ID: NCT02298959

Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumours.

Purpose:

  • This study is looking at the safety, side effects and best dose of a drug called ziv-aflibercept (Zaltrap®), when given along with pembrolizumab (MK-3475, Keytruda®) to treat patients with advanced solid tumours. This includes patients with metastatic or recurrent kidney cancer. Pembrolizumab is a newer immuno-oncology drug. Ziv-aflibercept is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), a targeted therapy drug. Patients who have had at least 1 prior targeted therapy with a VEGF TKI for their kidney cancer can take part in this study. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency Dr Daniel Renouf Vancouver, BC On hold
Princess Margaret Cancer Centre | University Health Centre Dr Lillian Siu Toronto, ON On hold

 

2 KIDNEY CANCER TYPE: Papillary
TRIAL ID: NCT02761057

Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (also called PAPMET Study).

Purpose:

  • This study is looking at how effective cabozantinib (Cometriq®, BMS-907351), or crizotinib (Xalkori®), or volitinib (AZD6094, Savolitinib), or sunitinib (Sutent®) each is in treating patients with papillary kidney cancer that is locally advanced or has spread (metastasized). Cabozantinib, crizotinib and volitinib are drugs called MET inhibitors. Sunitinib is a targeted tyrosine kinase inhibitor (TKI) therapy. This study is looking to see which of these drugs can stop the growth of tumour cells by blocking some of the enzymes needed for cell growth. Patients may have had prior surgery, 1 prior drug ( systemic) therapy or prior radiation therapy for advanced or metastatic kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute Dr Naveen S. Basappa Edmonton, AB Recruiting
Tom Baker Cancer Centre Dr Daniel Heng Calgary, AB Recruiting
London Regional Cancer Program Dr Kylea Potvin London, ON Recruiting
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Saint Joseph's Healthcare | Charlton Campus Dr Anil Kapoor Hamilton, ON Recruiting
Ottawa Hospital and Cancer Centre Dr Christina Canil Ottawa, ON Suspended
Centre hospitalier universitaire de Montréal - CHUM Dr Jean-Baptiste Lattouf Montréal, QC Recruiting
QEII Health Sciences Centre | Capital District Health Authority Dr Lori Wood  Halifax, NS Recruiting

 

3 KIDNEY CANCER TYPE: Clear and non-clear cell
TRIAL ID: NCT02639182

A Study of a Drug called AGS-16C3F compared to Axitinib in Patients with Metastatic Kidney Cancer.

Purpose:

  • AGS-16C3F is an experimental immuno-oncology drug. Axitinib (Inlyta®) is a targeted therapy drug used to treat kidney cancer. This study is for patients whose cancer continues to grow and they have had at least 2 prior drug therapies (for clear cell kidney cancer), or 1 prior drug therapy (for non-clear cell kidney cancer) and one of drugs was a targeted therapy with a VEGF inhibitor. This study is looking at the safety and how effective AGS-16C3F is when given by itself, compared to axitinib in patients when their kidney cancer has spread. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency   Vancouver, BC Closed
BCCA Centre for the Southern Interior   Kelowna, BC Closed
Cross Cancer Institute   Edmonton, AB Closed
Tom Baker Cancer Institute   Calgary, AB Closed
Juravinski Cancer Centre | Hamilton Health Sciences Centre Dr Sebastien Hotte Hamilton, ON On hold
London Health Sciences Centre Dr Scott Ernst London, ON  Closed

 

4 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02655822

A Study to Evaluate the Safety and Anti-cancer Activity of a Drug called CPI-444 Given by Itself and also in Combination With Another Drug, called Atezolizumab, in Patients with Advanced Cancers.

Purpose:

  • This study is looking at the safety and effectiveness of CPI-444, an experimental immuno-oncology drug when given by itself or along with atezolizumab (MPDL3280A, Tecentriq®), which is also an immuno-oncology drug. Patients may have had 1, but not more than 5 prior drug therapies for advanced, recurrent or progressing kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency Dr Daniel Renouf Vancouver, BC Recruiting
Cross Cancer Institute Dr Michael Sawyer Edmonton, AB Recruiting
Ottawa Hospital Cancer Centre Dr Rachel Goodwin Ottawa, ON  Recruiting

 

5 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02460224

Safety and Effectiveness of a Drug called LAG525, used by Itself and in Combination With another Drug called PDR001, in Patients With Advanced Cancer.

Purpose:

  • LAG525 and PDR001 are experimental immuno-oncology drugs. This study is looking at safety, effectiveness and dosing of these drugs in patients with solid tumours including kidney cancer. Patients with advanced or metastatic kidney cancer, who have at least 1 measurable lesion or mass and whose cancer has continued to grow despite prior treatment may take part in this study. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute   Edmonton, AB Recruiting
Princess Margaret Cancer Centre | University Health Network Dr Lillian Siu Toronto, ON Recruiting
Novartis Investigative Site - We do not have a list of participating centres. Talk to your doctor if you would like more information about this trial.   Toronto, ON Recruiting

 

6 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01638533

A Study of Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumours With Liver Dysfunction.

Purpose:

  • This study is looking at the side effects and best dose of romidepsin (Istodax®) to use to treat patients with various cancers. Patients with advanced, metastatic or recurrent kidney cancer and moderate or severe liver function problems may take part in this study. This study is for patients whose kidney cancer continues to grow or has come back (recurred) despite having standard treatments. Romidepsin is a chemotherapy drug used to treat certain types of lymphoma and may stop the growth of cancer cells by blocking the activity of proteins that are important for cancer cells to grow and survive. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network Dr Lillian Siu Toronto, ON Recruiting

 

7 KIDNEY CANCER TYPE: Renal medullary cancer or rhabdoid tumours of the kidney
TRIAL ID: NCT02601950

Study of the EZH2 Inhibitor Tazemetostat in Patients with INI1-Negative Tumours or Relapsed/Refractory Synovial Sarcoma. 

Purpose:

  • This study is looking at the side effects, safety and effectiveness of an experimental drug called tazemetostat (EPZ-6438), in patients with the uncommon types of kidney cancer – medullary and rhabdoid. Tazemetostat is a drug that targets and kills certain cancer cells by stopping a gene called EZH2 from working. This study is for patients whose cancer has spread (metastatic kidney cancer) for which there are no standard therapies available and their cancer has relapsed or is no longer responding to treatment (is refractory). Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute Dr Quincy Chu Edmonton, AB Recruiting
Princess Margaret Cancer Centre | University Health Network Dr Abha Gupta Toronto, ON Recruiting
Hôpital Royal Victoria (CUSM) | Royal Victoria Hospital (MUHC) Dr Thierry Alcindor Montréal, QC Recruiting

   

8 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT03173560

Safety and Effectiveness of Lenvatinib in Combination with Everolimus in Patients with Kidney Cancer (also called Hope Renal 218).

Purpose:

  • This trial is looking at the safety and effectiveness of 2 different doses of lenvatinib when given along with the drug everolimus for patients with clear cell kidney cancer. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor targeted therapy that may block signals that allow cancer cells to grow and multiply, and may also block the ones that help blood vessels grow. Everolimus (Afinitor®) is also a targeted therapy, but it is an mTOR inhibitor, so it works by blocking a certain protein that is important for cancer cells to grow, divide and survive. Everolimus is already used to treat kidney cancer. Lenvatinib is used to treat certain types of thyroid cancer. This study is for patients with advanced clear cell kidney cancer, who have had 1 prior vascular endothelial growth factor (VEGF)-targeted drug treatment for their kidney cancer. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency - Kelowna   Kelowna, BC Pending
Tom Baker Cancer Centre   Calgary, AB Recruiting
London Health Sciences Centre   London, ON Pending
Juravinski Cancer Centre   Hamilton, ON Pending
Odette Cancer Centre | Sunnybrook Health Sciences Centre Dr Georg Bjarnason Toronto, ON Recruiting
Ottawa Hospital   Ottawa, ON Recruiting
Hôpital général juif | Jewish General Hospital   Montréal, QC Recruiting

 

9 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02983045 

Dose Escalation and Expansion Study of NKTR-214 in Combination with Nivolumab or in Combination with Nivolumab and Ipilimumabin Patients With Certain Advanced or Metastatic Cancers, including Kidney Cancer (also called PIVOT-02).

Purpose:

  • This study is being done to find out the dose of NKTR-214 to give when used with nivolumab (Opdivo®). It is also studying how safe, effective and how a patient with advanced or metastatic kidney cancer tolerates the drug combination of NKTR-214 and nivolumab compared to nivolumab and  ipilimumab (Yervoy®) . All these drugs target the immune system and may work better together to kill cancer cells. NKTR-214 is an experimental drug that targets CD122 specific receptors found on the surface of immune cells.  Nivolumab is an immune-oncology drug, an anti PD-1 drug that is used as a second-line treatment for kidney cancer in Canada. Ipilimumab is also an immune-oncology drug, but it works on a different checkpoint protein (it is a CTLA-4 inhibitor drug). There are several parts to this study, some parts are for patients who have not had prior drug therapy for their kidney cancer, other patients can have had prior drug therapy. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
BC Cancer Agency   Vancouver, BC Pending
Odette Cancer Centre | Sunnybrook Health Sciences Centre   Toronto, ON Recruiting
Princess Margaret Cancer Centre | University Health Network Dr Philippe Bedard Toronto, ON Recruiting
Hôpital général juif | Jewish General Hospital   Montréal, QC Pending

 

10 KIDNEY CANCER TYPE: 
TRIAL ID: : NCT02996110

A Study to Test Combination (Immuno-oncology) Drug Treatments in Patients With Advanced Kidney Cancer (also called FRACTION-RCC).

Purpose:

  • This study is for patients with advanced or metastatic kidney cancer. It is being done to find out whether the drug nivolumab (Opdivo®) when given along with experimental drug therapies, is more effective than using the combination of nivolumab and ipilimumab (Yervoy®). Nivolumab, ipilimumab and relatlimab BMS-986016) and BMS-986205 are all immuno-oncology drugs, which each work in slightly different ways. One group of patients will be given the combination of nivolumab and ipilimumab. One group of patients will be given nivolumab and the experimental drug relatlimab (BMS-986016). Another group of patients will be given nivolumab and the experimental drug BMS-986205. This study does not specify if it is for kidney cancer patients who may or may not have had prior drug treatments, so please check with your doctor to see if this trial might be an option for you. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
R.S. McLaughlin Durham Regional Cancer Centre    Oshawa, ON Recruiting
Princess Margaret Centre | University Health Network   Toronto, ON Pending
Juravinski Cancer Centre | Hamilton Health Sciences Centre Dr Sebastien Hotte Hamilton, ON Recruiting
Hôpital général juif | Jewish General Hospital Dr Wilson H. Miller Jr Montréal, QC Recruiting
Hôptial Hôtel-Dieu de Québec - CHUQ Dr Vincent Fradet Québec, QC Recruiting

 

11 KIDNEY CANCER TYPE: 
TRIAL ID: NCT01968109

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of an Anti-LAG-3 (Relatlimab) With and Without an Anti-PD-1 (Nivolumab) in the Treatment of Solid Tumours.

Purpose:

  • This study is for patients with certain types of tumours including kidney cancer which has spread or cannot be removed by surgery. It is being done to find out how safe, effective and how a patient tolerates an experimental drug called relatlimab (BMS-986016) taken by itself or given along with the drug nivolumab (Opdivo®). Relatlimab and nivolumab are both immuno-oncology drugs, but they work in slightly different ways to improve the body’s immune system to fight cancer. One group of patients will be given relatilimab by itself and the other group of patients will be given relatlimab and nivolumab. This study is for kidney cancer patients who have not had any prior immune-oncology drug therapy. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Centre | University Health Network   Toronto, ON Pending
Hôpital Hôtel-Dieu de Québec Dr Joel Claveau Québec, QC Recruiting

 

12 KIDNEY CANCER TYPE: Clear cell or sarcomatoid components
TRIAL ID: NCT03289962

A Study of RO7198457 (Personalized Cancer Vaccine or PCV) by itself and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumours.

Purpose:

  • This study is for patients with certain types of tumours including those with incurable, advanced kidney cancer. It is being done to find out the safety, how a patient’s immune system responds to and how a patient tolerates an experimental drug called RO7198457, when taken by itself or along with the drug atezolizumab (Tecentriq®, MPDL3280A).  RO7198457 is an experimental immune-oncology drug therapy - a personalized cancer vaccine (PCV).  Atezolizumab is a newer immuno-oncology drug and a PD-L1 checkpoint inhibitor. One group of patients will be given RO7198457 by itself and the other group of patients will be given RO7198457 and atezolizumab. Different doses of RO7198457 will also be used. Kidney cancer patients whose cancer has progressed after having had at least one other standard treatment can take part in this study. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Ottawa Hospital Cancer Centre   Ottawa, ON Pending
Princess Margaret Centre | University Health Network Dr Lillian Siu Toronto, ON Pending

 

13 KIDNEY CANCER TYPE: Mainly clear cell
TRIAL ID: NCT03200717

Study of Effectiveness, Safety, and Quality of Life of Pazopanib in Patients With Advanced or Metastatic Kidney Cancer After Prior Checkpoint Inhibitor Treatment (also called IO-PAZ Study.)

Purpose:

  • This study is for patients with advanced or metastatic kidney cancer. It is being done to find out the safety and effectiveness of the drug pazopanib (Votrient®) when given after a patient has previously been given a first- or second-line treatment with an immune-oncology drug called an immune checkpoint inhibitor drug. Pazopanib is a targeted tyrosine kinase inhibitor (TKI) therapy. Find out more about this study
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Tom Baker Cancer Centre   Calgary, AB Recruiting
Novartis Investigative Site - We do not have a list of all participating centres. Talk to your doctor if you would like more information about this trial.   Toronto, ON Recruiting

 

14 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02737475

An Investigational Immuno-therapy Study of an Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab, in Combination with Ipilimumab, or a Combination of all 3 Drugs, in Patients With Solid Cancers That Are Advanced or Have Spread.

Purpose:

This study is for patients with advanced, metastatic or recurrent kidney cancer who have had at least one previous treatment. It is being done to find out the safety and effectiveness of an experimental drug called BMS-986178 given by itself or in combination with nivolumab (Opdivo®) and ipilimumab (Yervoy®). There are quite a few different groups that are involved in this study. One group of patients will just get the experimental drug BMS-986178. Another group of patients will get BMS-986178 and nivolumab. Another group with get BMS-986178 and ipilimumab. A different group will get BMS-986178, nivolumab and ipilimumab. Different doses and schedules of these drugs will also be studied. BMS-986178 is an experimental immuno-oncology drug, so it does not directly act on cancer cells but instead boosts the patient’s immune response to fight the cancer. Nivolumab and ipilimumab are also immune-oncology drugs. Find out more about this study.

HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute  Dr Quincy Chu Edmonton, AB Recruiting
Princess Margaret Hospital   Toronto, ON  Recruiting
The Ottawa Hospital   Ottawa, ON Recruiting

 

15 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02947165

Study of NIS793 Used by Itself, or in Combination With another Drug called PDR001, in Patients With Advanced Cancer.

Purpose:

NIS793 and PDR001 are experimental immuno-oncology drugs. This study is looking at safety, effectiveness and dosing of NIS793 used by itself compared to the combination of NIS793 and PDR001. Patients with advanced or metastatic kidney cancer, whose cancer has continued to grow despite prior treatment may take part in this study. Find out more about this study..

HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Novartis Investigative Site - We do not have a list of participating centres. Talk to your doctor if you would like more information about this trial.   Toronto, ON Recruiting

 

16 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT02724020

MLN0128 and MLN0128 plus MLN1117 Compared with Everolimus in the Treatment of Adults with Advanced or Metastatic Kidney Cancer.

Purpose:

  • This study is testing the safety and effectiveness of two new experimental drugs called MLN0128 and MLN1117. Everolimus is a targeted therapy mTOR inhibitor drug. MLN0128 is also an mTOR inhibitor, so it works like everolimus. MLN117 may work by blocking certain signaling pathways that can lead to uncontrolled cell growth and cancer. MLN0128 and MLN1117 are being tested to treat people with clear cell kidney cancer that is advanced or has spread to other parts of the body (metastasized). This study will also look at how these drugs are processed by the body. Patients may have had 1, but not more than 4 prior drug treatments for their kidney cancer. Patients will get either MLN0128 only, MLN0128 and MLN1117, or everolimus (Afinitor®), Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Cross Cancer Institute   Edmonton, AB Closed
CancerCare Manitoba Dr Piotr Czaykowski Winnipeg, MB Closed
Mc Master University   Hamilton, ON Closed
Hôpital Charles-Le Moyne | CISSS de la Montérégie-Centre  Dr Catherine Sperlich  Greenfield Park, QC Closed

  

17 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02608268

Safety and Effectiveness of MBG453 Used on Its Own and in Combination with PDR001 in Patients with Advanced Cancers.

Purpose:

  • MBG453 and PDR001 are experimental immuno-oncology drugs. This study is looking at safety, effectiveness and dosing of these drugs in patients with kidney cancer. Patients with advanced or metastatic cancer, who have at least 1 measurable lesion or mass, have had treatment for their kidney cancer and can no longer tolerate it, or their cancer has continued to grow despite prior treatment may take part in this study.Patients will get either MBC453 only, or MBG453 with PDR001. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Cancer Centre | University Health Network Dr Philippe Bedard Toronto, ON Closed
Novartis Investigative Site - We do not have a list of participating centres. Talk to your doctor if you would like more information about this trial.   Toronto, ON Closed

 

18 KIDNEY CANCER TYPE: Clear cell
TRIAL ID: NCT02089685

A Study to Evaluate the Safety and Effectiveness of Pembrolizumab (MK-3475) in Combination With Pegylated Interferon Alfa-2b and Pembrolizumab with Ipilimumab in Patients With Advanced Kidney Cancer (also called MK-3475-029 or KEYNOTE-29 Study).

Purpose:

  • This study is being done to see how safe, effective and how a patient with advanced or metastatic kidney cancer tolerates the drug combination of pembrolizumab and pegylated interferon alfa-2b (PegIFN-2b) compared to the drug combination of pembrolizumab and ipilimumab. This study is for patients with advanced or metastatic clear cell kidney cancer, who have been had at least 1 prior drug treatment for their kidney cancer. Pembrolizumab (MK-3475, Keytruda®) and ipilimumab (Yervoy ®) are both newer immuno-oncology drugs, but they target different checkpoint proteins. Pegylated interferon alfa-2b is a form of interferon - a cytokine - an immune hormone that is naturally made in the body. It is used to help fight certain viral infections.  Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Hôpital général juif | Jewish General Hospital Dr. Wilson H. Miller Jr Montréal, QC Closed
Merck Canada – We do not have a list of all participating centres. Talk to your doctor if you would like more information about this trial.   Kirkland, QC Closed

 

19 KIDNEY CANCER TYPE: 
TRIAL ID: NCT02118337

A Study to Evaluate the Safety and Antitumour Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab By Itself in Patients With Select Advanced Cancers.

Purpose:

  • This study is for patients with certain types of tumours, including those with advanced kidney cancer. It is being done to find out the safety and anticancer effect of an experimental drug called MEDI0680 (AMP-514) when it is given with the drug durvalumab (Imfinzi®). This drug combination will be compared to nivolumab (Opdivo®) therapy given by itself. MEDI0680 is an experimental immune-oncology drug. Durvalumab and nivolumab are both immune-oncology drugs. One group of patients will be given nivolumab. Other groups of patients will be given MEDI0680 and durvalumab and different doses of MEDI0680 and durvalumab will also be used and studied. Kidney cancer patients who have had at least one other drug treatment, as long as it was not an immune-oncology drug, can take part in this study. Find out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Centre | University Health Network Dr Aaron Hansen  Toronto, ON Closed
Hôpital général Juif - CIUSSS du Centre-Ouest de l'Île de Montréal Dr Wilson H. Miller Jr Montréal, QC Closed

Supportive Care Trials

Supportive care trials look at ways to improve the quality of life of kidney cancer patients and how best to manage the symptoms of cancer or side effects of treatment. These trials study new ways of helping kidney cancer patients cope with pain, problems with nutrition, diarrhea, nausea, and other health problems. Some of these trials may test drugs or might use different types of activities to see their effect on the patient living with kidney cancer and if their quality of life is improved.

Note: When available, the researcher in charge of the study, called the Principal Investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be mentioned

 

1 KIDNEY CANCER TYPE: 
TRIAL ID: : NCT03520231

A Study Comparing Denosumab With Standard Treatment in Patients with Urinary Cancers, including Kidney Cancer, Who Have Bone Metastases.

Purpose:

  • This study is for patients with kidney cancer that has spread to the bone (metastatic kidney cancer). It is being done to find out how effective denosumab (Xgeva®) is in helping patients with bone metastases from kidney and other urinary (urothelial) cancers. This study will compare denosumab plus standard treatment, to a placebo and standard treatment. The standard treatment for urothelial cancer is a combination of chemotherapy drugs - gemcitabine (Gemzar®) and cisplatin (Platinol®), or gemcitabine and carboplatin (Paraplatin®)Denosumab is a drug that helps control the activity of cells that break down bone.A placebo is an inactive drug or treatment that looks like and is given the same way as the active drug or treatment in the trialFind out more about this study.
HOSPITAL | CANCER CENTRE PRINCIPAL INVESTIGATOR LOCATION TRIAL STATUS
Princess Margaret Centre | University Health Network Dr Srikala Sridhar Toronto, ON Recruiting

I found a clinical trial : What next?

If you find a clinical trial that may be of interest to you, take the information to your physician to discuss it in more detail. Please REGISTER with Kidney Cancer Canada and join the Discussion Forum to reach out to other patients participating in a clinical trial or to ask a specific question.

SHOULD I JOIN A CLINICAL TRIAL?